JOHN W. FROST, M.D., F.A.C.P.; MANFRED I. GOLDWEIN, M.D.; JAMES A. BRYAN, M.D.
Vincaleukoblastine or vinblastine sulfate (VLB) is a recent addition to the chemotherapy of malignant disease. Unlike most of the older drugs of proven benefit, which are either alkylating agents or compounds acting in competitive inhibition with purines and pyrimidines, this agent is an alkaloid whose chemical mode of action may well prove to be different. Earlier reports have shown it to have a favorable effect in Hodgkin's disease (1, 2) and in metastatic choriocarcinoma (3). While some effects in metastatic cancers of other types have been described, these were transient.
The drug is extracted from the common flowering shrub, the
FROST JW, GOLDWEIN MI, BRYAN JA. Clinical Experience with Vincaleukoblastine in Far-advanced Hodgkin's Disease and Various Malignant States. Ann Intern Med. ;56:854–859. doi: 10.7326/0003-4819-56-6-854
Download citation file:
Published: Ann Intern Med. 1962;56(6):854-859.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use